MindWalk (HYFT) investor relations material

Business overview and platform evolution

• Transitioning from a project-based discovery business to a recurring data platform for top pharmaceutical clients, leveraging 20 years of curated biology and trusted relationships with 19 of the top 20 global pharma companies.

• Launched ReefIQ, a context layer platform, in June 2026, now in enterprise negotiations with multiple large pharma companies; LensAI provides model-neutral reasoning and applications.

• Platform model enables multi-year, recurring revenue that grows as clients run more programs, with ~80% of the commercial funnel now structured as platform relationships.

• Internal pipeline applies proprietary capabilities to MindWalk-owned programs, advancing preclinical assets in GLP-1, dengue, and influenza.

Financial performance and funding

• Achieved 21% revenue growth in Q1 FY27 to $3.8M, with gross margin expanding to 59% from 48%; gross profit up 47%.

• Operating cash used decreased to $4.0M despite higher spend; net loss from continuing operations was $6.1M, reflecting planned sales and marketing investment.

• Secured a US$30M senior unsecured revolving credit facility at a 7% fixed rate, providing two years of runway without equity dilution.

Technology and competitive advantages

• Platform is defensible due to 20 years of expert curation, compounding value with each program, model-neutrality, and outputs grounded in curated biology.

• AMD and Vultr partnerships enable rapid, scalable compute for drug discovery, reducing screening time and cost while supporting enterprise client onboarding.

• Proprietary HYFT database contains 660 million biological patterns and 25 billion relationships, underpinning the platform's unique value.